Neurotech International's Phase II/III Clinical Trial Results

Neurotech International Limited (ASX: $NTI) has reported significant improvements in Autism Spectrum Disorder (ASD) patients participating in the Phase II/III clinical trial. The analysis demonstrates a 56% improvement in ASD symptoms after 12 weeks of NTI164 therapy, with patients re-classified as borderline ill on the Clinical Global Impression - Severity of illness Scale (CGI-S).

Executive Commentary on Trial Results

Dr Thomas Duthy, Executive Director of Neurotech, expressed satisfaction with the results, stating, 'The results once again confirm the benefits conferred are drug-related with a rapid clinical onset of improvement. Moreover, patients who have received NT1164 for 12 weeks in total continued to improve following the primary analysis at 8 weeks, so much so their symptoms are barely noticeable. In general, this means substantial lifestyle improvements for the patient and their caregivers, which makes us very proud to be supporting these clinical trials in autism.'

Summary of Neurotech International's Announcement

Neurotech International (ASX: $NTI) has announced further beneficial improvements in ASD patients participating in the Phase II/III clinical trial. The results demonstrate a 56% improvement in ASD symptoms after 12 weeks of NTI164 therapy, with patients re-classified as borderline ill on the CGI-S scale. The company continues to see significant improvements in patients receiving NTI164, and no serious adverse events related to NTI164 were observed. The successful trial paves the way for potential lifestyle improvements for patients and their caregivers, reflecting Neurotech's commitment to supporting clinical trials in autism.